Financial Performance - The company's total revenue for the first half of 2025 was 584 million yuan, a decrease of 40.2% year-on-year [1] - The net profit attributable to shareholders was -56.12 million yuan, representing a decline of 1075.89% compared to the previous year [1] - In Q2 2025, total revenue was 296 million yuan, down 39.65% year-on-year, with a net profit of -41.80 million yuan, a decrease of 427.14% [1] Cost and Expenses - The proportion of operating expenses (including financial, sales, and management expenses) increased significantly, accounting for 25.99% of total revenue, up 51.49% year-on-year [1] - Total expenses for the three categories amounted to 152 million yuan [1] Profitability Metrics - The gross margin was 22.39%, an increase of 17.34% year-on-year, while the net margin was -8.84%, a decrease of 1132.63% [1] - Earnings per share were -0.29 yuan, a decline of 1350.0% year-on-year [1] Financial Health Indicators - Cash and cash equivalents decreased to 122 million yuan, down 40.44% year-on-year [1] - The company's debt situation is concerning, with interest-bearing liabilities at 829 million yuan, a decrease of 22.95% [1] - The company's asset-liability ratio for interest-bearing debt reached 37.64% [4] Historical Performance - The company's historical return on invested capital (ROIC) has been relatively low, with a median of 8.68% since its listing, and a particularly poor ROIC of -6.55% in 2024 [3] - The company has reported losses in four out of its eight annual reports since going public [3]

Core Viewpoint - The report highlights the significant decline in revenue and profit for Thalys Medical Technology Group in the first half of 2025, attributed to strategic business restructuring and external market pressures, while emphasizing ongoing investments in smart healthcare and AI technologies for future growth [3][4][5]. Financial Performance - The company reported a revenue of approximately 583.5 million yuan, a decrease of 40.20% compared to the same period last year [3][4]. - The total profit for the period was a loss of approximately 51.93 million yuan, a decline of 495.76% year-on-year [3][4]. - The net profit attributable to shareholders was approximately -56.12 million yuan, down from -4.77 million yuan in the previous year [3][4]. - The net cash flow from operating activities was -79.17 million yuan, worsening from -48.88 million yuan year-on-year [3][4]. Industry Context - The healthcare industry in China continues to grow steadily, driven by increasing healthcare spending, an aging population (22% aged 60 and above), and supportive government policies [5][6]. - The medical device market is projected to reach approximately 2.4 trillion yuan by 2029, with a compound annual growth rate of 16% [7]. - The implementation of DRG/DIP payment reforms is pushing healthcare institutions towards refined operational management, while the demand for high-quality medical services remains concentrated in top-tier hospitals [7][8]. Strategic Initiatives - The company is focusing on transforming traditional medical supply chain services into intelligent healthcare solutions, with increased R&D investments in smart hospitals and medical big data analysis platforms [4][10]. - Thalys Medical is actively expanding its market presence in regions like Henan and Sichuan, while also exploring opportunities in Yunnan, Chongqing, and Guizhou [10][11]. - The company has established partnerships with major hospitals and is recognized as a key player in the SPD (Supply Chain Management) and IVD (In Vitro Diagnostics) sectors, enhancing its competitive edge [10][11]. Technological Advancements - The company is leveraging AI and big data technologies to develop comprehensive smart hospital solutions, aiming to improve operational efficiency and resource allocation in healthcare institutions [12][13]. - Thalys Medical is also investing in brain science and digital therapy, with significant growth expected in the cognitive disorder digital therapy market, projected to reach 4.2 billion USD by 2025 [14][15]. - The company is collaborating with various institutions to advance AI applications in clinical decision-making and disease management, enhancing its service offerings in the healthcare sector [18][19].

| 公司代码：603716 | 塞力斯医疗科技集团股份有限公司2025 | 年半年度报告摘要 | | | --- | --- | --- | --- | | | 公司简称：塞力医疗 | | | | | 塞力斯医疗科技集团股份有限公司 | | | | | 塞力斯医疗科技集团股份有限公司2025 年半年度报告摘要 | | | | | 第一节 重要提示 | | | | 展规划，投资者应当到 | www.sse.com.cn 网站仔细阅读半年度报告全文。 | | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | 无 | | | | | | 第二节 公司基本情况 | | | | | 公司股票简况 | | | | 股票种类 | 股票上市交易所 股票简称 | 股票代码 | 变更前股票 | | 简称 | | | | | A股 | 上海证券交易所 塞力医疗 | 603716 | 塞力斯 | | 联系人和联系方式 | 董事会秘书 | | 证券事务代表 | | 姓名 | 范莉 | 不适用 | | | 电话 | 027-83386020 | | | | 办公地址 | 武汉市东西湖 ...

Group 1 - The meeting of Cyrus Medical Technology Group Co., Ltd. is scheduled for September 15, 2025, at 14:00 [3][8] - Shareholders must arrive on time and are allowed to participate in voting only if they are present before the voting starts [1][2] - The company will cancel the supervisory board, transferring its responsibilities to the audit committee of the board of directors [6][7] Group 2 - The company plans to change its registered capital from RMB 190,952,305 to RMB 210,139,246 due to the conversion of convertible bonds [7] - The company has issued 5,433,100 convertible bonds with a total amount of RMB 54,331,000, which began conversion on March 1, 2021 [7] - The company will revise its articles of association to comply with updated laws and regulations [9][11] Group 3 - The voting process will be conducted through both on-site and online methods, with specific time slots for voting [5][8] - The meeting will include a series of agenda items, including the reading and deliberation of proposals, shareholder speeches, and voting [8][11] - Legal opinions will be provided by a law firm present at the meeting [3]

Meeting Information - The shareholders' meeting is scheduled for September 15, 2025, at 14:00 [1] - The meeting will be held at the company's conference room located at 1310 Jinshan Avenue, Dongxihu District, Wuhan [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange network voting system from 9:15 to 15:00 on the day of the meeting [1][2] - Multiple shareholder accounts can be used to aggregate voting rights, but repeated votes will be counted based on the first submission [3] - There are no public solicitations for shareholder voting rights [2] Attendance and Registration - Only shareholders registered by the close of trading on September 10, 2025, are eligible to attend the meeting [3][4] - Both individual and corporate shareholders must present valid identification and, if applicable, a power of attorney for their representatives [4] Agenda Items - The meeting will review several non-cumulative voting proposals that have been approved by the company's board [2] - Specific proposals include amendments to the company's articles of association and other governance matters [6] Additional Information - Shareholders are responsible for their own travel and accommodation expenses related to attending the meeting [4] - Contact information for the company is provided for any inquiries regarding the meeting [4]

Core Points - The company has decided to cancel its supervisory board, transferring its responsibilities to the audit committee of the board of directors, in order to enhance corporate governance and comply with regulatory requirements [1][2] - The company's registered capital will be increased from RMB 190,952,305 to RMB 210,139,246 due to the conversion of convertible bonds, resulting in an increase in total shares from 190,952,305 to 210,139,246 [2][3] - Amendments to the company's articles of association will be made to reflect the cancellation of the supervisory board and the changes in registered capital [3][4] Company Structure Changes - The supervisory board will be abolished, and its functions will be assumed by the audit committee of the board of directors [1][2] - The current members of the supervisory board will no longer hold their positions following the cancellation [2] Capital Changes - The company issued 5,433,100 convertible bonds with a total value of RMB 54,331,000, which began conversion on March 1, 2021 [2] - The total number of shares will increase by 19,186,941 shares due to the conversion of the bonds [2] Articles of Association Amendments - The articles of association will be revised to reflect the cancellation of the supervisory board and the increase in registered capital [3][4] - Specific articles will be updated to maintain compliance with the latest laws and regulations [3][4]

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the status of the funds raised by Seirus Medical Technology Group Co., Ltd. It highlights the termination of certain fundraising projects and the reallocation of remaining funds to enhance liquidity and operational efficiency in response to changing market conditions. Fundraising Overview - In 2018, the company raised approximately RMB 625.96 million through a non-public offering of A-shares, with a net amount of RMB 607.61 million after expenses [1][2] - As of June 30, 2025, the remaining balance of the non-public fundraising was RMB 8.99 million, including interest [2] Fund Usage and Management - By June 30, 2025, the company had utilized RMB 202.78 million of the funds raised from the 2020 convertible bond issuance, leaving a balance of RMB 333.89 million [4] - The company has established dedicated bank accounts for the management of the raised funds, ensuring compliance with regulatory requirements [7][18] Project Termination and Fund Reallocation - The company decided to terminate the "Expansion of Medical Testing Integrated Marketing and Service Business Scale Project" due to significant changes in the market environment and profitability concerns, reallocating the remaining RMB 172.54 million to enhance liquidity [28][29] - The decision was made after thorough evaluations and was approved in board meetings held in June 2025 [28] Financial Management Practices - The company has implemented a structured approach to manage the raised funds, including regular audits and checks by the finance department to ensure proper usage [7][24] - The company has also utilized idle funds temporarily to supplement working capital, with repayments made as scheduled [24][31] Regulatory Compliance - The company has adhered to various regulations regarding fundraising and fund management, including the establishment of tripartite agreements with banks and sponsors to ensure proper oversight [7][18][22]

Core Points - The document outlines the management rules for the shares held by directors and senior management of Celis Medical Technology Group Co., Ltd, emphasizing compliance with relevant laws and regulations [1][2] - The rules apply to shares registered in the names of directors and senior management, including those held in others' accounts and through margin trading [2][4] - Specific restrictions are placed on share transfers under certain conditions, such as resignation, legal investigations, and company violations [4][5] Share Management - Directors and senior management are prohibited from transferring shares under specific circumstances, including within six months of resignation or during ongoing investigations [4] - A maximum of 25% of their total shares can be transferred annually, with exceptions for certain legal situations [5][6] - If a director or senior management holds fewer than 1,000 shares, they may transfer all shares at once without restriction [6] Information Disclosure - The company secretary is responsible for managing the identity and shareholding data of directors and senior management, ensuring timely reporting of any changes [11][12] - Directors and senior management must notify the board secretary of their trading plans before buying or selling shares [12][13] - Any changes in shareholding must be disclosed within two trading days, including details such as the number of shares before and after the change [11][16] Additional Provisions - The rules will be implemented upon approval by the board and will be subject to relevant laws and regulations [13][18] - The board is responsible for interpreting these rules [13][19]

塞力斯医疗科技集团股份有限公司 累积投票实施细则 塞力斯医疗科技集团股份有限公司 累积投票实施细则 （2025 年 8 月） 第五条 股东会投票选举董事前，大会主持人应宣读累积投票制的说明，并 就股东对累积投票的相关问题予以解答。该说明可以采用如下举例的方法，介绍 累积投票的投票方式："本次选举 N 名董事，如股东持有公司有表决权股份 10 万股，则该股东共享有 10×N 票的表决权。该股东可以将 10×N 票集中投给一 名董事候选人，也可以将 10×N 票分散投给数个候选人。" 第六条 公司股东可以将其享有的全部投票权数，集中投向候选人中的其中 一人，也可以分散投向数人，但其累积投票权数不得超过本实施细则第五条规定 的投票权总数。 塞力斯医疗科技集团股份有限公司 累积投票实施细则 第七条 适用累积投票制度选举公司董事的具体步骤如下： （一） 股东会选举董事时，投票股东必须在一张选票上注明所选举的所有 董事，并在其选举的每名董事后标注其使用的投票权数目； （二） 如果选票上该股东使用的投票权总数小于或等于其所合法拥有的投 票数目，则该选票有效； 第一条 为进一步规范塞力斯医疗科技集团股份有限公司（以下简称"公 ...

塞力斯医疗科技集团股份有限公司 信息披露管理制度 塞力斯医疗科技集团股份有限公司 信息披露管理制度 （2025 年 8 月） 第一章 总则 第一条 为了规范塞力斯医疗科技集团股份有限公司（以下简称"公司"） 的信息披露行为，加强信息披露事务管理，保护投资者合法权益，根据《中华人 民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司信息披露管理办法》《上海证券交易所股票上市规则》等法律法规、规章、 规范性文件及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章 程》"）的规定，制定本制度。 第二条 信息披露义务人应当及时依法履行信息披露义务，披露的信息应当 真实、准确、完整，简明清晰、通俗易懂，不得有虚假记载、误导性陈述或者重 大遗漏。 信息披露义务人披露的信息应当同时向所有投资者披露，不得提前向任何单 位和个人泄露。但是，法律、行政法规另有规定的除外。 在内幕信息依法披露前，内幕信息的知情人和非法获取内幕信息的人不得公 开或者泄露该信息，不得利用该信息进行内幕交易。任何单位和个人不得非法要 求信息披露义务人提供依法需要披露但尚未披露的信息。 公司证券及其衍生品种同时在境内境外 ...